Elevance Health Reports Strong Earnings But Faces Medicare Advantage Compliance Issues
Elevance Health, based in Indianapolis, exceeded expectations with its first-quarter earnings, reporting adjusted earnings of $12.58 per share. The company also raised its full-year earnings guidance, showcasing strong business performance and enhanced claims processing efficiency, as noted by CEO Gail Boudreaux.
Alongside these financial results, Elevance disclosed a $935 million charge related to potential liabilities from Medicare Advantage billing discrepancies. This charge reflects the company's estimate of financial impacts arising from noncompliant billing practices with federal regulations.
According to documents from the Securities and Exchange Commission and the Centers for Medicare & Medicaid Services (CMS), Medicare Advantage plans receive payments based on members' health risk scores. Insurers must ensure diagnosis code accuracy and correct discrepancies within 60 days. CMS identified noncompliance in Elevance's submissions, including unauthorized data methods like encrypted USB flash drives used from November 2018 to October 2025.
The use of these methods led to significant noncompliance, as highlighted by CMS. Elevance failed to certify data accuracy, which likely resulted in unreturned government overpayments from unsupported diagnosis codes. CFO Mark Kaye described the issue as a policy and payment mechanism dispute involving risk adjustment corrections.
CEO Boudreaux addressed these historical disputes on a recent earnings call, stating they do not reflect current operations. CMS extended the compliance deadline to July 31, potentially allowing Elevance to avoid sanctions if corrections are implemented. Membership shifts, including a 15.8% decrease in Medicare Advantage enrollment, highlight Elevance's strategic market adjustments alongside industry peers like UnitedHealthcare, Humana, and Aetna.
UnitedHealth Group reported first-quarter revenue of $111.7 billion, surpassing expectations and enhancing full-year earnings guidance. Their decreased medical loss ratio indicates operational efficiency, contrasting with Elevance's higher ratio, which reflects increased costs, especially in Medicaid. Elevance's strategic reduction in Medicare Advantage coverage aligns with efforts to maintain profitability within government program frameworks.
Elevance projects an adjusted full-year EPS of at least $26.75 and plans to continue dividends and stock buybacks. The company is leveraging artificial intelligence to enhance operational efficiencies, claiming reduced prior authorization denials. Market reactions to Elevance's disclosures were steady, while UnitedHealth's positive performance boosted sector confidence, underscoring compliance and expenditure impacts industry-wide.